Serum homocysteine level and eye involvement in Egyptian patients with Behçet’s disease

Hassan, 2012, Subclinical atherosclerosis in Behçet’s disease, Turk J Rheumatol, 27, 109, 10.5606/tjr.2012.016 Wechsler, 1999, Cardiovascular manifestations of Behçet’s disease, Ann Med Interne, 150, 542 Kitaichi, 2007, Ocular features of Behçet’s disease: an international collaborative study, Br J Ophthalmol, 91, 1573, 10.1136/bjo.2007.123554 Cekmen, 2003, Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s syndrome, Int J Dermatol, 42, 870, 10.1046/j.1365-4362.2003.01688.x Glueck, 1995, Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients, Am J Cardiol, 75, 132, 10.1016/S0002-9149(00)80061-2 Cattaneo, 1998, High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications?, Thromb Haemost, 80, 542 Mason, 1992, The effects of vitamins B12, B6 and folate and blood homocysteine levels, Ann NY Acad Sci, 669, 197, 10.1111/j.1749-6632.1992.tb17100.x Morgan, 1998, Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention, J Rheumatol, 25, 441 Turgan, 1999, Plasma homocysteine levels in acute coronary syndromes, Jpn Heart J, 40, 729, 10.1536/jhj.40.729 Kartal Durmazlar, 2008, Homocysteine may involve in the pathogenesis of Behçet’s disease by inducing inflammation, Mediators Inflamm, 2008, 407972, 10.1155/2008/407972 Cahill, 2003, Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease, Am J Ophthalmol, 136, 1136, 10.1016/S0002-9394(03)00571-3 Pianka, 2000, Hyperhomocysteinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion, Ophthalmology, 107, 1588, 10.1016/S0161-6420(00)00181-0 Vine, 2000, Hyperhomocysteinemia: a risk factor for central retinal vein occlusion, Am J Ophthalmol, 129, 640, 10.1016/S0002-9394(99)00476-6 Brown, 2002, Homocysteine: a risk factor for retinal venous occlusive disease, Ophthalmology, 109, 287, 10.1016/S0161-6420(01)00923-X Lahey, 2002, Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56years of age, Ophthalmology, 109, 126, 10.1016/S0161-6420(01)00842-9 Van Cott, 2004, Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis, Blood Coagul Fibrinolysis, 15, 393, 10.1097/01.mbc.0000114442.59147.8d Lahey, 2003, Hypercoagulable states and central retinal vein occlusion, Curr Opin Pulm Med, 9, 385, 10.1097/00063198-200309000-00008 Calikoglu, 2002, Serum homocysteine level in Behçet’s disease, Hematologia, 3, 219, 10.1163/15685590260461039 Korkmaz, 2002, Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet’s syndrome?, Clin Exp Rheumatol, 20, S30 1990, Criteria for the diagnosis of Behçet’s disease, Lancet, 335, 1078 Feki, 2004, Hyperhomocysteinaemia is associated with uveitis but not with deep venous thrombosis in Behçet’s disease, Clin Chem Lab Med, 42, 1417, 10.1515/CCLM.2004.263 Nussenblatt, 1997, Uveitis in Behçet’s disease, Int Rev Immunol, 14, 67, 10.3109/08830189709116845 Gheita, 2013, Serum level of APRIL/BLyS in Behçet’s disease patients: clinical significance in uveitis and disease activity, Mod Rheumatol, 23, 542, 10.3109/s10165-012-0694-x Kaklamani, 1998, Behçet’s disease, Semin Arthritis Rheum, 27, 197, 10.1016/S0049-0172(98)80001-2 Zouboulis, 1997, Epidemiological features of Adamantiades–Behçet’s disease in Germany and in Europe, Yonsei Med J, 38, 411, 10.3349/ymj.1997.38.6.411 Aflaki, 2008, The relation between serum homocysteine level and eye involvement in Behçet’s disease, Arch Iran Med, 11, 625 Altinbas, 2000, Hyperhomocysteinemia and activated protein C resistance in Behçet’s disease, J Intern Med, 248, 267, 10.1046/j.1365-2796.2000.00711.x Aksu, 2001, Hyperhomocysteinemia in Behçet’s disease, Rheumatology (Oxford), 40, 687, 10.1093/rheumatology/40.6.687 Canataroglu, 2003, Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet’s disease, Rheumatol Int, 23, 236, 10.1007/s00296-003-0301-8 Ates, 2005, Serum homocysteine level is higher in Behçet’s disease with vascular involvement, Rheumatol Int, 25, 42, 10.1007/s00296-003-0398-9 Mungan, 2006, Lipid peroxidation and homocysteine levels in Behçet’s disease, Clin Chem Lab Med, 44, 1115, 10.1515/CCLM.2006.191 Ozkan, 2007, Assessment of homocysteine, neopterin, and nitric oxide levels in Behçet’s disease, Clin Chem Lab Med, 45, 73, 10.1515/CCLM.2007.018 Ozdemir, 2004, Vascular endothelial function and plasma homocysteine levels in Behçet’s disease, Am J Cardiol, 94, 522, 10.1016/j.amjcard.2004.04.073 Shahram, 2010, Plasma homocysteine level in patients with Behçet’s disease with or without thrombosis, Arch Iran Med, 13, 476 Hamzaoui, 2010, Hyperhomocysteinaemia in Behçet’s disease, Biochem Res Int, 2010, 361387, 10.1155/2010/361387 Genest, 1999, Hyperhomocyst(e)inemia determining factors and treatment, Can J Cardiol, 15, 35 Monnerat, 1997, Homocysteine and venous thromboembolism, Schweiz Med Wochenschr, 127, 1489 Harpel, 1996, Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis, J Nutr, 126, 1285, 10.1093/jn/126.suppl_4.1285S Ridker, 2001, High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease, Circulation, 103, 1813, 10.1161/01.CIR.103.13.1813